Tuesday, April 22, 2025
Home Tags Citius

Tag: citius

@NCI
CoronaVirus

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in...

Editor / Curator -
Citius, Biotech Stock Review
2020 Watch List

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

Editor / Curator -
Biotech News

Where is Citius Pharma (CTXR) in the FDA Approval Process?

Editor / Curator -
Citius Pharma
2020 Watch List

Citius Pharma (CTXR) On The Move.

Editor / Curator -
Superbug News - CoronaVirus Watch List

New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and...

Editor / Curator -
Citius, Biotech Stock Review
Biotech News

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal...

Editor / Curator -
steven boyd, biotech stock review
Biotech News

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

Editor / Curator -
candida auris, citius pharma, biotech stock review
Biotech News

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

Editor / Curator -

Latest article

Epidemic Denial: RFK Jr. Holds Press Conference on new Autism findings from the CDC

All News Editor / Curator -
Health and Human Services Secretary Robert F. Kennedy Jr. will be joined by officials on Wednesday to discuss the latest Autism and...

GeoVax (GOVX) Down on JFK’s Continued Scale Backs to the Vaccine Sector.

2025 Watch List Editor / Curator -
Down 20% in response to news in an 8K that the Biomedical Advanced Research and Development Authority BARDA (also once known as the...

Adding Allarity (ALLR) $0.70, to Watch List.

2025 Watch List Editor / Curator -
LIVE QUOTE SHORT TERM CHART Bargain Hunting? Adding to the...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.